<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK299312" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK299312/" /><meta name="ncbi_pagename" content="Riboflavin Transporter Deficiency Neuronopathy - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Riboflavin Transporter Deficiency Neuronopathy - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Riboflavin Transporter Deficiency Neuronopathy" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2015/06/11" /><meta name="citation_author" content="Andreea Manole" /><meta name="citation_author" content="Henry Houlden" /><meta name="citation_pmid" content="26072523" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK299312/" /><meta name="citation_keywords" content="Brown-Vialetto-Van Laere (BVVL) Syndrome" /><meta name="citation_keywords" content="Fazio-Londe Syndrome" /><meta name="citation_keywords" content="Solute carrier family 52, riboflavin transporter, member 2" /><meta name="citation_keywords" content="Solute carrier family 52, riboflavin transporter, member 3" /><meta name="citation_keywords" content="SLC52A2" /><meta name="citation_keywords" content="SLC52A3" /><meta name="citation_keywords" content="Riboflavin Transporter Deficiency Neuronopathy" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Riboflavin Transporter Deficiency Neuronopathy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Andreea Manole" /><meta name="DC.Contributor" content="Henry Houlden" /><meta name="DC.Date" content="2015/06/11" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK299312/" /><meta name="description" content="Riboflavin transporter deficiency neuronopathy is characterized by motor neuronopathy (manifest as proximal and distal limb weakness, often with severe distal wasting and breathing problems due to paralysis of the diaphragm), sensory neuronopathy (manifest as gait ataxia), and cranial neuronopathy (manifest as optic atrophy, sensorineural deafness, and bulbar palsy). Onset is usually in infancy or in childhood before age eight years; however, on occasion individuals with genetically confirmed disease present in the third decade. When untreated, most infants with riboflavin transporter deficiency rapidly become ventilator dependent and die in the first years of life. In the majority of affected individuals the initial finding is sensorineural deafness, which is usually progressive and severe. The time between the onset of deafness and the development of other manifestations varies but is usually one to two years. In some individuals an intercurrent event, usually an injury or infection, appears to precipitate the initial manifestations or worsen existing findings." /><meta name="og:title" content="Riboflavin Transporter Deficiency Neuronopathy" /><meta name="og:type" content="book" /><meta name="og:description" content="Riboflavin transporter deficiency neuronopathy is characterized by motor neuronopathy (manifest as proximal and distal limb weakness, often with severe distal wasting and breathing problems due to paralysis of the diaphragm), sensory neuronopathy (manifest as gait ataxia), and cranial neuronopathy (manifest as optic atrophy, sensorineural deafness, and bulbar palsy). Onset is usually in infancy or in childhood before age eight years; however, on occasion individuals with genetically confirmed disease present in the third decade. When untreated, most infants with riboflavin transporter deficiency rapidly become ventilator dependent and die in the first years of life. In the majority of affected individuals the initial finding is sensorineural deafness, which is usually progressive and severe. The time between the onset of deafness and the development of other manifestations varies but is usually one to two years. In some individuals an intercurrent event, usually an injury or infection, appears to precipitate the initial manifestations or worsen existing findings." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK299312/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/riboflavin-tn/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK299312/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D4509E0400B110000000005F80235.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK299312_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK299312_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/rcdp/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/rbs/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK299312_"><span class="title" itemprop="name">Riboflavin Transporter Deficiency Neuronopathy</span></h1><p class="contrib-group"><span itemprop="author">Andreea Manole</span>, BSc and <span itemprop="author">Henry Houlden</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK299312_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK299312_ai__"><div class="contrib half_rhythm"><span itemprop="author">Andreea Manole</span>, BSc<div class="affiliation small">MRC Centre for Neuromuscular Diseases<br />UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery<br />London, United Kingdom<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ku.ca.lcu@31.elonam.aeerdna" class="oemail">ku.ca.lcu@31.elonam.aeerdna</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Henry Houlden</span>, MD, PhD<div class="affiliation small">Department of Molecular Neurosciences and MRC Centre for Neuromuscular Diseases<br />UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery<br />London, United Kingdom<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ku.ca.lcu@nedluoh.h" class="oemail">ku.ca.lcu@nedluoh.h</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">June 11, 2015</span>.</p><p><em>Estimated reading time: 25 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="riboflavin-tn.Summary" itemprop="description"><h2 id="_riboflavin-tn_Summary_">Summary</h2><div><h4 class="inline">Clinical description.</h4><p>Riboflavin transporter deficiency neuronopathy is characterized by motor neuronopathy (manifest as proximal and distal limb weakness, often with severe distal wasting and breathing problems due to paralysis of the diaphragm), sensory neuronopathy (manifest as gait ataxia), and cranial neuronopathy (manifest as optic atrophy, sensorineural deafness, and bulbar palsy). Onset is usually in infancy or in childhood before age eight years; however, on occasion individuals with genetically confirmed disease present in the third decade. When untreated, most infants with riboflavin transporter deficiency rapidly become ventilator dependent and die in the first years of life. In the majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals the initial finding is sensorineural deafness, which is usually progressive and severe. The time between the onset of deafness and the development of other manifestations varies but is usually one to two years. In some individuals an intercurrent event, usually an injury or infection, appears to precipitate the initial manifestations or worsen existing findings.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of riboflavin transporter deficiency neuronopathy is based on clinical, neurophysiologic, neuroimaging, and laboratory findings as well as the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in either <i>SLC52A2</i> or <i>SLC52A3</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> High-dose oral supplementation of riboflavin between 10 mg and 50 mg/kg/day improves symptoms and signs on clinical examination, improves objective testing (vital capacity, brain stem evoked potentials, nerve conduction studies), and normalizes acylcarnitine levels. The optimal dose is as yet unknown.</p><p>Because oral riboflavin supplementation is effective (and possibly life saving), it should begin as soon as a riboflavin transporter deficiency neuronopathy is suspected and continued lifelong unless the diagnosis is excluded by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p>Supportive care includes: respiratory support; physiotherapy to avoid contractures; occupational therapy to support activities of daily living; orthotics for limb and trunk bracing; speech and language therapy to avoid choking and respiratory problems; wheel chair as needed; low vision aids as needed; routine management of scoliosis to avoid long-term respiratory problems; and routine management of depression.</p><p><i>Surveillance:</i> At three months and six months after initiation of riboflavin supplementation: follow-up physical and neurologic examinations, and measurement of blood riboflavin/FAD/FMN and acylcarnitine analysis. Thereafter, follow up should be biannual in older individuals and more frequent in younger children.</p><p><i>Agents/circumstances to avoid:</i> Dietary restriction of riboflavin.</p><p><i>Evaluation of relatives at risk:</i> When the <i>SLC52A2</i> or <i>SLC52A3</i> pathogenic variants in the family are known, it is appropriate to perform <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> on the older and younger sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual to identify as early as possible those who would benefit from early treatment with riboflavin supplementation and monitoring for potential complications of the disorder.</p><p><i>Pregnancy management:</i> Females who have riboflavin transporter neuronopathy or are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>SLC52A2</i> or <i>SLC52A3</i> should have riboflavin supplements before and during pregnancy and when breast feeding to avoid inducing riboflavin deficiency in the baby.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Riboflavin transporter deficiency neuronopathy is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>), and a 25% chance of being unaffected and not a carrier. Heterozygote (carrier) testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the <i>SLC52A2</i> or <i>SLC52A3</i> pathogenic variants in the family are known.</p></div></div><div id="riboflavin-tn.GeneReview_Scope"><h2 id="_riboflavin-tn_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="riboflavin-tn.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK299312/table/riboflavin-tn.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__riboflavin-tn.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_riboflavin-tn.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Riboflavin Transporter Deficiency Neuronopathy: Included Phenotypes</th></tr></thead><tbody><tr><td headers="hd_h_riboflavin-tn.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Brown-Vialetto-Van Laere (BVVL) syndrome</div></li><li class="half_rhythm"><div>Fazio-Londe syndrome</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#riboflavin-tn.Nomenclature">Nomenclature</a>.</p></div></dd></dl></div></div></div></div><div id="riboflavin-tn.Diagnosis"><h2 id="_riboflavin-tn_Diagnosis_">Diagnosis</h2><p>Riboflavin transporter deficiency neuronopathy is a phenotypic continuum of motor, sensory, and cranial nerve neuronopathy caused by pathogenic variants in either <i>SLC52A2</i> or <i>SLC52A3</i> and including the following previously recognized disorders [<a class="bk_pop" href="#riboflavin-tn.REF.fazio.1892.327">Fazio 1892</a>, <a class="bk_pop" href="#riboflavin-tn.REF.londe.1894.212">Londe 1894</a>, <a class="bk_pop" href="#riboflavin-tn.REF.dipti.2005.443">Dipti et al 2005</a>, <a class="bk_pop" href="#riboflavin-tn.REF.green.2010.485">Green et al 2010</a>, <a class="bk_pop" href="#riboflavin-tn.REF.johnson.2010.567">Johnson et al 2010</a>, <a class="bk_pop" href="#riboflavin-tn.REF.johnson.2012.2875">Johnson et al 2012</a>, <a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al 2014</a>]:</p><ul><li class="half_rhythm"><div>Brown-Vialetto-Van Laere (BVVL) syndrome</div></li><li class="half_rhythm"><div>Fazio-Londe syndrome; similar to BVVL syndrome but lacking cranial nerve VIII involvement (i.e., deafness)</div></li></ul><div id="riboflavin-tn.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Riboflavin transporter deficiency neuronopathy should be suspected in individuals with the following clinical, neurophysiologic, neuroimaging, and laboratory findings of motor, sensory, and cranial nerve neuronopathy [<a class="bk_pop" href="#riboflavin-tn.REF.gomez.1962.317">Gomez et al 1962</a>, <a class="bk_pop" href="#riboflavin-tn.REF.alexander.1976.66">Alexander et al 1976</a>, <a class="bk_pop" href="#riboflavin-tn.REF.mcshane.1992.1889">McShane et al 1992</a>, <a class="bk_pop" href="#riboflavin-tn.REF.sathasivam.2000.277">Sathasivam et al 2000</a>, <a class="bk_pop" href="#riboflavin-tn.REF.dipti.2005.443">Dipti et al 2005</a>, <a class="bk_pop" href="#riboflavin-tn.REF.sathasivam.2008.9">Sathasivam 2008</a>, <a class="bk_pop" href="#riboflavin-tn.REF.bosch.2011.159">Bosch et al 2011</a>, <a class="bk_pop" href="#riboflavin-tn.REF.horvath.2012.679">Horvath 2012</a>, <a class="bk_pop" href="#riboflavin-tn.REF.bandettini_di_poggio.2014.141">Bandettini Di Poggio et al 2014</a>, <a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al 2014</a>, <a class="bk_pop" href="#riboflavin-tn.REF.manole.2014.506">Manole et al 2014</a>].</p><p><b>Clinical features</b> consist of progressive childhood onset* of the following:</p><ul><li class="half_rhythm"><div><b>Motor</b> neuronopathy:</div><ul><li class="half_rhythm"><div>Affecting upper limbs more than lower limbs, resulting in weakness, involving proximal and distal limb musculature, often with severe distal wasting. Deep tendon reflexes are consistently absent.</div></li><li class="half_rhythm"><div>Resulting in axial weakness, manifest as severe trunk and neck weakness requiring trunk bracing and difficulty with holding the head up</div></li><li class="half_rhythm"><div>Resulting in paralysis of the diaphragm which can result in respiratory insufficiency</div></li></ul></li><li class="half_rhythm"><div><b>Sensory</b> neuronopathy manifesting as gait ataxia</div></li><li class="half_rhythm"><div><b>Cranial</b> neuronopathy:</div><ul><li class="half_rhythm"><div>Typically affecting cranial nerves II (optic atrophy variably associated nystagmus), VIII (sensorineural hearing loss), IX and X (bulbar palsy), and XII (tongue fasciculations, weakness, and atrophy)</div></li><li class="half_rhythm"><div>Occasionally affecting cranial nerves III (ptosis) and VII (facial weakness)</div></li></ul></li></ul><p>Cognition is usually preserved.</p><p><b>*</b>Note: Onset age range is a few months to early teen years, and very rarely in adulthood.</p><p><b>Neurophysiologic studies</b></p><ul><li class="half_rhythm"><div>Electromyogram shows chronic partial denervation.</div></li><li class="half_rhythm"><div>Nerve conduction studies show a sensory &#x0003e; motor axonal neuronopathy. Motor nerve conduction velocities are usually normal.</div></li><li class="half_rhythm"><div>Sensory nerve action potentials are often absent.</div></li><li class="half_rhythm"><div>Visual evoked potentials are frequently abnormal.</div></li><li class="half_rhythm"><div>Brain stem audiometry evoked response has universally shown sensorineural deafness.</div></li><li class="half_rhythm"><div>EEG (electroencephalogram) may show an excess of theta activity or slow waves [<a class="bk_pop" href="#riboflavin-tn.REF.rosemberg.1982.84">Rosemberg et al 1982</a>].</div></li></ul><p><b>Brain MRI</b> is usually normal; however, in a small number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals cerebellar atrophy and hyperintense areas in the brain stem and cerebral peduncles are observed.</p><p><b>Laboratory findings.</b> Acylcarnitine profile in blood is abnormal with accumulation of short and medium-chain (and sometimes long-chain) acylcarnitines in some but not all individuals with genetically confirmed riboflavin transporter deficiency neuronopathy [<a class="bk_pop" href="#riboflavin-tn.REF.bosch.2012.83">Bosch et al 2012</a>, <a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al 2014</a>].</p><p>It should be noted that even in children diagnosed in the first months of life with abnormal acylcarnitine profiles, <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> bloodspots demonstrated normal acylcarnitine profiles, probably due to sufficient maternal riboflavin supply to the unborn infant [<a class="bk_pop" href="#riboflavin-tn.REF.bosch.2011.159">Bosch et al 2011</a>].</p></div><div id="riboflavin-tn.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of riboflavin transporter deficiency neuronopathy is based on the clinical, neurophysiologic, neuroimaging, and laboratory findings described above as well as the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in either <i>SLC52A2</i> or <i>SLC52A3</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (<a class="figpopup" href="/books/NBK299312/table/riboflavin-tn.T.molecular_genetic_testin/?report=objectonly" target="object" rid-figpopup="figriboflavintnTmoleculargenetictestin" rid-ob="figobriboflavintnTmoleculargenetictestin">Table 1</a>).</p><p>Molecular testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Simultaneous <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>SLC52A2</i> and <i>SLC52A3</i> is performed first and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found in either <i>SLC52A2</i> or <i>SLC52A3</i>. Note: Although subtle differences are observed in the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of individuals with pathogenic variants in <i>SLC52A2</i> compared with the phenotype of individuals with pathogenic variants in <i>SLC52A3</i>, the phenotypes are sufficiently similar that both genes should be tested at the same time rather than sequentially.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>SLC52A2</i> and <i>SLC52A3</i> as well as other genes of interest selected on potentially similar clinical presentations (see <a href="#riboflavin-tn.Differential_Diagnosis">Differential Diagnosis</a>) may also be used. Multigene panels have been developed to include <i>SLC52A1</i>, <i>SLC52A2</i>, <i>SLC52A3</i>, <i>ETFA</i>, <i>ETFB</i>, <i>ETFDH</i>, <i>IGHMBP</i>, <i>ALSIN</i>, <i>ALADIN</i>, and <i>UBQLN1</i> [<a class="bk_pop" href="#riboflavin-tn.REF.manole.2014.506">Manole et al 2014</a>, <a class="bk_pop" href="#riboflavin-tn.REF.angelini.2015.615">Angelini 2015</a>]. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><p>Note: Because oral riboflavin supplementation is effective (and possibly lifesaving), it should begin as soon as a riboflavin transporter deficiency neuronopathy is suspected and continued lifelong unless the diagnosis is excluded by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><div id="riboflavin-tn.T.molecular_genetic_testin" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Riboflavin Transporter Deficiency Neuronopathy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK299312/table/riboflavin-tn.T.molecular_genetic_testin/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__riboflavin-tn.T.molecular_genetic_testin_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of Riboflavin Transporter Deficiency Neuronopathy Attributed to Pathogenic Variants in Gene</th><th id="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr><tr><th headers="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_3" id="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3,&#x000a0;4</sup></th><th headers="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_3" id="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></th></tr></thead><tbody><tr><td headers="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC52A2</i></td><td headers="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~30%</td><td headers="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_3 hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13/13 probands&#x000a0;<sup>6</sup></td><td headers="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_3 hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No large deletions/duplications&#x000a0;<sup>7</sup></td></tr><tr><td headers="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC52A3</i></td><td headers="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~70%</td><td headers="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_3 hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">18/18 probands&#x000a0;<sup>8</sup></td><td headers="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_3 hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No large deletions/duplications&#x000a0;<sup>7</sup></td></tr><tr><td headers="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>9</sup></td><td headers="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_3 hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_1_3 hd_h_riboflavin-tn.T.molecular_genetic_testin_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="riboflavin-tn.TF.1.1"><p class="no_margin">See <a href="/books/NBK299312/#riboflavin-tn.Genetic_Counseling">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="riboflavin-tn.TF.1.2"><p class="no_margin">See <a href="#riboflavin-tn.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>3. </dt><dd><div id="riboflavin-tn.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="riboflavin-tn.TF.1.4"><p class="no_margin">All variants have been detected using <a class="def" href="/books/n/gene/glossary/def-item/sanger-sequencing/">Sanger sequencing</a> or next-generation <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and then Sanger sequencing confirmation.</p></div></dd><dt>5. </dt><dd><div id="riboflavin-tn.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="riboflavin-tn.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al [2014]</a> provide the most extensive screening of <i>SLC52A2</i>: 13 of 72 probands with cranial neuronopathy, sensorimotor neuronopathy, and respiratory insufficiency were found to have <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants. Other smaller case series and individual families have been reported as well.</p></div></dd><dt>7. </dt><dd><div id="riboflavin-tn.TF.1.7"><p class="no_margin">No large deletions/duplications identified using <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> microarray analysis (CMA) [Manole et al, unpublished data]</p></div></dd><dt>8. </dt><dd><div id="riboflavin-tn.TF.1.8"><p class="no_margin">Manole [unpublished data] provides the most extensive screening of <i>SLC52A3</i>: Eighteen of 116 individuals with cranial neuropathy and sensorimotor neuropathy &#x000b1; respiratory insufficiency were found to have <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants. Other smaller series and individual families have been reported as well.</p></div></dd><dt>9. </dt><dd><div id="riboflavin-tn.TF.1.9"><p class="no_margin">A number of individuals with cranial neuropathy and sensorimotor neuropathy &#x000b1; respiratory insufficiency have not had pathogenic variants identified using <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/sanger-sequencing/">Sanger sequencing</a> [Manole unpublished data]. In a number of individuals large deletions/duplications in <i>SLC52A1</i>, <i>SLC52A2,</i> and <i>SLC52A3</i> (see <a href="#riboflavin-tn.Molecular_Genetics">Molecular Genetics</a>) were excluded using CMA [Manole et al, unpublished data].</p></div></dd></dl></div></div></div></div></div><div id="riboflavin-tn.Clinical_Characteristics"><h2 id="_riboflavin-tn_Clinical_Characteristics_">Clinical Characteristics</h2><div id="riboflavin-tn.Clinical_Description"><h3>Clinical Description</h3><p>Riboflavin transporter deficiency neuronopathy is characterized by motor neuronopathy (manifest as proximal and distal limb weakness, often with severe distal wasting [<a class="bk_pop" href="#riboflavin-tn.REF.bandettini_di_poggio.2014.141">Bandettini Di Poggio et al 2014</a>, <a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al 2014</a>, <a class="bk_pop" href="#riboflavin-tn.REF.manole.2014.506">Manole et al 2014</a>] and breathing problems), sensory neuronopathy (manifest as gait ataxia), and cranial neuronopathy (manifest as optic atrophy, sensorineural deafness, and bulbar palsy).</p><p>Onset is usually in infancy or in childhood before age eight years, although on occasion individuals with genetically confirmed disease present in the third decade.</p><p>Typically, after a symptom-free first few weeks (or in some cases months) of life, infants become floppy with failure to thrive and rapidly developing respiratory insufficiency due to paralysis of the diaphragm, followed (in order of appearance) by:</p><ul><li class="half_rhythm"><div>Infantile- or early childhood-onset nystagmus</div></li><li class="half_rhythm"><div>Early childhood-onset sensory (gait) ataxia</div></li><li class="half_rhythm"><div>Childhood onset sensorineural deafness</div></li><li class="half_rhythm"><div>Weakness and atrophy of the upper limbs (first distally then proximally)</div></li><li class="half_rhythm"><div>Weakness of neck extensors and later trunk muscles</div></li><li class="half_rhythm"><div>Tongue fasciculations and atrophy with increased swallowing problems</div></li><li class="half_rhythm"><div>Respiratory insufficiency due to muscle weakness</div></li></ul><p>Other initial presenting features can include stridor, slurring of speech, and facial weakness. Visual problems due to optic atrophy are common [<a class="bk_pop" href="#riboflavin-tn.REF.gomez.1962.317">Gomez et al 1962</a>, <a class="bk_pop" href="#riboflavin-tn.REF.alexander.1976.66">Alexander et al 1976</a>, <a class="bk_pop" href="#riboflavin-tn.REF.summers.1987.440">Summers et al 1987</a>, <a class="bk_pop" href="#riboflavin-tn.REF.abarbanel.1991.349">Abarbanel et al 1991</a>, <a class="bk_pop" href="#riboflavin-tn.REF.dipti.2005.443">Dipti et al 2005</a>, <a class="bk_pop" href="#riboflavin-tn.REF.nemoto.2005">Nemoto et al 2005</a>, <a class="bk_pop" href="#riboflavin-tn.REF.descatha.2006.187">Descatha et al 2006</a>, <a class="bk_pop" href="#riboflavin-tn.REF.malheiros.2007.32">Malheiros et al 2007</a>, <a class="bk_pop" href="#riboflavin-tn.REF.miao.2007.214">Miao et al 2007</a>, <a class="bk_pop" href="#riboflavin-tn.REF.dakhil.2010.397">Dakhil et al 2010</a>, <a class="bk_pop" href="#riboflavin-tn.REF.green.2010.485">Green et al 2010</a>, <a class="bk_pop" href="#riboflavin-tn.REF.bosch.2011.159">Bosch et al 2011</a>, <a class="bk_pop" href="#riboflavin-tn.REF.bandettini_di_poggio.2014.141">Bandettini Di Poggio et al 2014</a>, <a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al 2014</a>, <a class="bk_pop" href="#riboflavin-tn.REF.manole.2014.506">Manole et al 2014</a>, <a class="bk_pop" href="#riboflavin-tn.REF.srour.2014.775">Srour et al 2014</a>].</p><p>Untreated, most infants diagnosed with riboflavin transporter deficiency neuronopathy rapidly become ventilator dependent (often for some years at home or on intensive care units) and most die before age 12 years [<a class="bk_pop" href="#riboflavin-tn.REF.bandettini_di_poggio.2014.141">Bandettini Di Poggio et al 2014</a>, <a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al 2014</a>, <a class="bk_pop" href="#riboflavin-tn.REF.manole.2014.506">Manole et al 2014</a>].</p><p>In the majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals presenting after infancy the initial finding is sensorineural deafness, which is usually progressive and severe. The time between the onset of deafness and the development of other symptoms varies but is usually one to two years. Very rarely affected individuals do not develop deafness, and sometimes deafness appears later in the disease course.</p><p>With improved disease management and riboflavin treatment, life span is likely to increase; however, treatment with riboflavin has only been reported since 2010 [<a class="bk_pop" href="#riboflavin-tn.REF.bosch.2011.159">Bosch et al 2011</a>, <a class="bk_pop" href="#riboflavin-tn.REF.horvath.2012.679">Horvath 2012</a>, <a class="bk_pop" href="#riboflavin-tn.REF.bandettini_di_poggio.2014.141">Bandettini Di Poggio et al 2014</a>, <a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al 2014</a>, <a class="bk_pop" href="#riboflavin-tn.REF.manole.2014.506">Manole et al 2014</a>].</p><p>In some individuals an intercurrent event, usually an injury or infection, appears to precipitate the initial symptoms or worsen existing symptoms [<a class="bk_pop" href="#riboflavin-tn.REF.gallai.1981.259">Gallai et al 1981</a>, <a class="bk_pop" href="#riboflavin-tn.REF.voudris.2002.732">Voudris et al 2002</a>, <a class="bk_pop" href="#riboflavin-tn.REF.bandettini_di_poggio.2014.141">Bandettini Di Poggio et al 2014</a>].</p><p>Other neurologic features can include: occasional sensory involvement, retinitis pigmentosa and macular hyperpigmentation, autonomic dysfunction, and epilepsy.</p><p>The phenotypes caused by pathogenic variants in <i>SLC52A2</i> are difficult to differentiate from those caused by pathogenic variants in <i>SLC52A3</i>; however, in individuals with pathogenic variants in <i>SLC52A2</i> early-onset weakness in the upper limbs and neck is almost invariable &#x02013; in contrast to those with pathogenic variants in <i>SLC52A3</i> or genetically unclassified Brown-Vialetto-Van Laere (BVVL) syndrome, in whom the onset of weakness is often more generalized [<a class="bk_pop" href="#riboflavin-tn.REF.green.2010.485">Green et al 2010</a>, <a class="bk_pop" href="#riboflavin-tn.REF.bosch.2011.159">Bosch et al 2011</a>, <a class="bk_pop" href="#riboflavin-tn.REF.bosch.2012.83">Bosch et al 2012</a>, <a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al 2014</a>].</p><p><b>Other neurophysiologic studies.</b> Electrocardiogram showed incomplete right bundle branch block in one individual [<a class="bk_pop" href="#riboflavin-tn.REF.m_garban_.2000.117">M&#x000e9;garban&#x000e9; et al 2000</a>].</p><p>Sleep studies demonstrated predominantly central sleep apnea with minimal obstructive sleep apnea in one individual [<a class="bk_pop" href="#riboflavin-tn.REF.miao.2007.214">Miao et al 2007</a>].</p><p>CSF protein is often raised but &#x0003c;1 g/dL [<a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al 2014</a>].</p><p><b>Pathology.</b> Few pathologic descriptions of riboflavin transporter deficiency neuronopathy are available. The authors know of only one pathologic description of an archival genetically confirmed case; however, findings were similar to those in individuals who had not undergone <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> [<a class="bk_pop" href="#riboflavin-tn.REF.johnson.2010.567">Johnson et al 2010</a>]. There was usually neuronal injury and loss in cranial nerve nuclei III, V, VI and lower cranial nerve nuclei (VII &#x02013; XII); depletion of spinal anterior horn cells, lateral columns, and pyramidal tracts; and degeneration of cerebellar Purkinje cells and basal ganglia [<a class="bk_pop" href="#riboflavin-tn.REF.rosemberg.1982.84">Rosemberg et al 1982</a>, <a class="bk_pop" href="#riboflavin-tn.REF.summers.1987.440">Summers et al 1987</a>, <a class="bk_pop" href="#riboflavin-tn.REF.abarbanel.1991.349">Abarbanel et al 1991</a>].</p></div><div id="riboflavin-tn.GenotypePhenotype_Correlat"><h3>Genotype-Phenotype Correlations</h3><p>To date no <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> have been identified in <i>SLC52A2</i> or <i>SLC52A3</i> [Author, personal observation]<i>.</i></p></div><div id="riboflavin-tn.Nomenclature"><h3>Nomenclature</h3><p>Childhood-onset progressive bulbar palsy developing in the first and second decade of life was traditionally separated into Brown-Vialetto-Van Laere (BVVL) syndrome and Fazio-Londe syndrome (a BVVL-like syndrome without deafness). It is now known that Brown-Vialetto-Van Laere syndrome and Fazio-Londe syndrome are caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in either <i>SLC52A2</i> or <i>SLC52A3</i>.</p><p><a class="bk_pop" href="#riboflavin-tn.REF.bosch.2012.83">Bosch et al [2012]</a> and <a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al [2014]</a> have proposed new BVVL syndrome nomenclature to clarify the specific mechanism of disease: riboflavin transporter deficiency neuronopathy, type 2 (corresponding with <i>SLC52A2</i>-associated disease) and riboflavin transporter deficiency neuronopathy, type 3 (corresponding with <i>SLC52A3</i>-associated disease).</p><p>BVVL syndrome was first reported in 1894 by Charles Brown as an "infantile" form of ALS with associated hearing loss [<a class="bk_pop" href="#riboflavin-tn.REF.brown.1894.707">Brown 1894</a>]. The male index case manifested an acute onset of bulbar weakness, hearing loss and respiratory insufficiency at age 12 years, with rapid progression of symptoms and later involvement of the upper limbs as well as "general arrest of development and emaciation." The report of three sibs with pontobulbar paralysis and associated hearing loss by Dr. Ernesto Vialetto in 1936 [<a class="bk_pop" href="#riboflavin-tn.REF.vialetto.1936.1">Vialetto 1936</a>] followed by the report of three sisters with similar clinical features by MJ Van Laere in 1966 resulted in the term BVVL syndrome being used to describe this pontobulbar palsy [<a class="bk_pop" href="#riboflavin-tn.REF.van_laere.1966.289">Van Laere 1966</a>].</p><p>Hereditary progressive bulbar palsy without deafness has also been described and referred to as Fazio-Londe syndrome [<a class="bk_pop" href="#riboflavin-tn.REF.fazio.1892.327">Fazio 1892</a>, <a class="bk_pop" href="#riboflavin-tn.REF.londe.1894.212">Londe 1894</a>]; it was initially described in a mother and her son and later reported in two brothers with a more rapidly progressive syndrome.</p></div><div id="riboflavin-tn.Prevalence"><h3>Prevalence</h3><p>Although riboflavin transporter deficiency neuronopathy is a relatively rare condition, it appears to be more prevalent than previously thought given the advent of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>, which has improved diagnostic capabilities [<a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al 2014</a>]. Based on the number of individuals screened for pathogenic variants in <i>SLC52A2</i> and <i>SLC52A3</i>, the authors estimate 70 new diagnoses worldwide per year; however, it is difficult to provide a precise figure at this stage [Manole et al, unpublished data based on genetic referral numbers].</p></div></div><div id="riboflavin-tn.Genetically_Related_Alleli"><h2 id="_riboflavin-tn_Genetically_Related_Alleli_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>SLC52A2</i> or <i>SLC52A3</i>.</p><p>Sporadic tumors (including esophageal squamous cell carcinomas) occurring as single tumors in the absence of any other findings of this syndrome frequently harbor somatic pathogenic variants in <i>SLC52A3</i> that are <b>not</b> present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>; thus, predisposition to these tumors is not heritable. For more details see Molecular Genetics, <a href="#riboflavin-tn.Cancer_and_Benign_Tumors">Cancer and Benign Tumors</a>.</p></div><div id="riboflavin-tn.Differential_Diagnosis"><h2 id="_riboflavin-tn_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Multiple acyl-CoA dehydrogenase deficiency (MADD)</b> (also known as glutaric acidemia II or glutaric aciduria II) (OMIM <a href="http://omim.org/entry/231680" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">231680</a>) can be caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in at least three different genes: <i>ETFA</i>, <i>ETFB</i>, and <i>ETFDH</i>. These genes are all involved in electron transfer in the mitochondrial respiratory chain [<a class="bk_pop" href="#riboflavin-tn.REF.olsen.2007.2045">Olsen et al 2007</a>, <a class="bk_pop" href="#riboflavin-tn.REF.law.2009.95">Law et al 2009</a>].</p><p>The clinical features of MADD are grouped into three types:</p><ul><li class="half_rhythm"><div>Neonatal-onset form with <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> anomalies (type I)</div></li><li class="half_rhythm"><div>Neonatal-onset form without <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> anomalies (type II)</div></li><li class="half_rhythm"><div>Late-onset form (type III)</div></li></ul><p>The neonatal-onset forms, which are usually fatal, are characterized by severe hypoketotic hypoglycemia, metabolic acidosis, multisystem involvement, and excretion of large amounts of fatty acid- and amino acid-derived metabolites.</p><p>Symptoms and age at presentation of late-onset MADD are highly variable and characterized by proximal muscle weakness, recurrent episodes of lethargy, vomiting, hypoglycemia, metabolic acidosis, and hepatomegaly often preceded by metabolic stress [<a class="bk_pop" href="#riboflavin-tn.REF.law.2009.95">Law et al 2009</a>]. Neuronopathy is not observed in MADD.</p><p>In MADD acylcarnitine analysis usually reveals increased concentrations of several short-chain, medium-chain, and long-chain acylcarnitines. In individuals with late-onset disease, abnormalities may be mild, atypical, or only detectable during decompensation.</p><p><b>Spinal muscular atrophy with respiratory distress type 1 (SMARD1)</b> (OMIM <a href="http://omim.org/entry/604320" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">604320</a>) is an "SMA plus" syndrome caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>IGHMBP2</i> (encoding immunoglobulin mu-binding protein 2), usually leading to early-onset severe axonal polyneuronopathy with distal muscle and lower-limb weakness and respiratory failure due to diaphragmatic paralysis. Infantile onset is most common. There may also be autonomic involvement, pneumonia, and hypotonia; deafness has not been described [<a class="bk_pop" href="#riboflavin-tn.REF.yiu.2008.930">Yiu et al 2008</a>].</p><p><a href="/books/n/gene/sma/"><b>Spinal muscular atrophy</b></a> (caused by pathogenic variants in <i>SMN1</i>) mostly involves the anterior horn cells of motor neurons; however, some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals may have peripheral motor and sensory nerve involvement [<a class="bk_pop" href="#riboflavin-tn.REF.yiu.2008.930">Yiu et al 2008</a>].</p><p><b>Nathalie syndrome</b> (OMIM <a href="http://omim.org/entry/255990" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">255990</a>) has no lower cranial nerve signs but includes deafness and weakness in addition to spinal muscular atrophy (SMA), cataracts, hypogonadism, and cardiac conduction defects [<a class="bk_pop" href="#riboflavin-tn.REF.cremers.1975.330">Cremers et al 1975</a>, <a class="bk_pop" href="#riboflavin-tn.REF.sathasivam.2008.9">Sathasivam 2008</a>].</p><p><b>Madras motor neuron disease (MMND)</b> (also referred to as Madras pattern motor neuron disease), a rare young age-onset progressive neuromuscular disease with a relatively benign course, has predominantly been observed in southern India. Multiple cranial nerve palsies particularly involve the seventh and ninth to 12th cranial nerves. Hearing impairment is present in all patients; optic atrophy is present in some. Although the majority are <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family), a few <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cases have been reported. The etiology is unknown; mutation of <i>SLC52A2</i> and <i>SLC52A3</i> as well as <i>C9orf72</i> has been excluded [<a class="bk_pop" href="#riboflavin-tn.REF.valmikinathan.1973.753">Valmikinathan et al 1973</a>, <a class="bk_pop" href="#riboflavin-tn.REF.shankar.2000.428">Shankar et al 2000</a>, <a class="bk_pop" href="#riboflavin-tn.REF.nalini.2013.119">Nalini et al 2013</a>].</p><p><b>Facial onset sensory motor neuronopathy (FOSMN)</b> is a recently described under-recognized, rare, slowly progressive bulbar onset motor and sensory neuronopathy [<a class="bk_pop" href="#riboflavin-tn.REF.vucic.2012.73">Vucic et al 2012</a>]. Although there are marked similarities to classic bulbar-onset motor neuron disease, FOSMN differs clinically by the striking facial-onset sensory deficits with subsequent development of motor deficits, slow evolution in a rostral-caudal direction, and a much better prognosis. The finding of TDP-43 pathology in an individual with FOSMN suggests an overlap with motor neuron disease, although further evidence and studies are needed. The <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> variant Asp90Ala was identified in <i>SOD1</i> in a patient with FOSMN [<a class="bk_pop" href="#riboflavin-tn.REF.dalla_bella.2014.1009">Dalla Bella et al 2014</a>]; its role in causation of MND is unclear.</p><p><b>Allgrove or triple A syndrome</b> (OMIM <a href="http://omim.org/entry/231550" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">231550</a>), caused by pathogenic variants in <i>ALADIN,</i> is a rare <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorder that has prominent bulbar features, although achalasia, alacrima, and adrenal problems are the primary manifestations [<a class="bk_pop" href="#riboflavin-tn.REF.houlden.2002.2681">Houlden et al 2002</a>]. Of note, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals also have an abnormal, small fissured tongue similar to that of individuals with amyotrophic lateral sclerosis (ALS) [<a class="bk_pop" href="#riboflavin-tn.REF.houlden.2009.1366">Houlden 2009</a>, <a class="bk_pop" href="#riboflavin-tn.REF.manole.2014.506">Manole et al 2014</a>].</p><p><a href="/books/n/gene/als-overview/">Amyotrophic lateral sclerosis</a> (ALS) is characterized by adult-onset degeneration of motor neurons in the corticospinal tract and brain stem, and the anterior horn cells of the spinal cord. Patients have upper motor neuron (UMN) and lower motor neuron (LMN) limb signs with progressive muscle weakness and wasting, fasciculations, and spasticity. Patients often die of respiratory paralysis [<a class="bk_pop" href="#riboflavin-tn.REF.hardiman.2011.639">Hardiman et al 2011</a>]. BVVL has been described as an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> juvenile form of ALS since both BVVL and ALS have bulbar and LMN involvement. BVVL differs from ALS in that BVVL includes deafness and has an earlier age of onset and a more irregular disease course; UMN limb signs are not invariably present [<a class="bk_pop" href="#riboflavin-tn.REF.hardiman.2011.639">Hardiman et al 2011</a>].</p><p>Of note, pathogenic variants in <i>UBQLN2</i> (encoding ubiquilin 2<i>)</i> have been identified as a rare cause of ALS; a recent study has identified a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> variant in a related <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (<i>UBQLN1</i>) previously linked to neurodegeneration in an individual with BVVL and an atypical early-onset ALS with bulbar palsy and hearing loss. Although the pathogenicity of this variant remains uncertain, this finding highlights the overlap of the BVVL and ALS phenotypes [<a class="bk_pop" href="#riboflavin-tn.REF.gonz_lezp_rez.2012.391">Gonz&#x000e1;lez-P&#x000e9;rez et al 2012</a>].</p></div><div id="riboflavin-tn.Management"><h2 id="_riboflavin-tn_Management_">Management</h2><div id="riboflavin-tn.Evaluations_Following_Init"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with riboflavin transporter deficiency neuronopathy, the following are recommended:</p><ul><li class="half_rhythm"><div>Evaluation by a neuromuscular specialist with attention to possible weakness, sensory loss, gait disturbance, and need for bracing</div></li><li class="half_rhythm"><div>Sleep study and pulmonary consultation</div></li><li class="half_rhythm"><div>Ophthalmologic evaluation with attention to visual acuity and possible optic atrophy</div></li><li class="half_rhythm"><div>Audiologic assessment</div></li><li class="half_rhythm"><div>Other consultations depending on clinical problems; for example, orthopedic consultation if scoliosis is present or psychiatry consultation if depression is present</div></li><li class="half_rhythm"><div>Rehabilitation assessments: physiotherapy, occupational therapy, orthotics, speech and language therapy, wheel chair clinic</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="riboflavin-tn.Treatment_of_Manifestation"><h3>Treatment of Manifestations</h3><div id="riboflavin-tn.Medications"><h4>Medications</h4><p><b>High dose supplementation</b>
<b>of</b>
<b>riboflavin.</b> Because oral riboflavin supplementation is effective (and possibly life saving), it should begin as soon as a riboflavin transporter deficiency neuronopathy is suspected and continued lifelong unless the diagnosis is excluded by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p>High-dose supplementation of riboflavin between 10 mg and 50 mg/kg/day has been effective in patients with genetically confirmed riboflavin transporter deficiency neuronopathy and also in some patients in whom the genetic basis of riboflavin transporter deficiency neuronopathy has not been established.</p><p>Although no formal placebo control trial has been conducted and the longest course of riboflavin supplementation has been 36 months, riboflavin supplementation: improves symptoms and signs on clinical examination; improves objective testing (vital capacity, brain stem evoked potentials, nerve conduction studies), and normalizes acylcarnitine levels [<a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al 2014</a>].</p><p>Before initiating riboflavin supplementation, perform the assessments in <a href="#riboflavin-tn.Evaluations_Following_Init">Evaluations Following Initial Diagnosis</a>.</p><p>Oral riboflavin supplementation should be given in gradually increasing doses in order to establish the optimum dose:</p><ul><li class="half_rhythm"><div>Riboflavin 10 mg/kg per day in 3 doses for 1 month</div></li><li class="half_rhythm"><div>Riboflavin 20 mg/kg per day in 3 doses for 1 month</div></li><li class="half_rhythm"><div>Riboflavin 30 mg/kg per day in 3 doses for 1 month</div></li><li class="half_rhythm"><div>Riboflavin 40 mg/kg per day in 3 doses for 1 month</div></li><li class="half_rhythm"><div>Riboflavin 50 mg/kg per day in 3 doses for 1 month</div></li></ul><p>Note: Some patients are on doses up to 70 mg/kg/day.</p><p>Side effects, problems, or deterioration at any point require discussion with the treating clinician.</p><p>See <a href="#riboflavin-tn.Surveillance">Surveillance</a> for recommended follow up of individuals treated with riboflavin supplementation.</p><p>Note: Treatments attempted before the basis of riboflavin transporter deficiency neuronopathy was known have included the following:</p><ul><li class="half_rhythm"><div>Intravenous immunoglobulin (IVIG) has been tried in a number of patients with reports of improvement as well as reports of no or non-sustained response [<a class="bk_pop" href="#riboflavin-tn.REF.bandettini_di_poggio.2014.141">Bandettini Di Poggio et al 2014</a>].</div></li><li class="half_rhythm"><div>Some patients have reported additional improvement with other multivitamins and coenzyme Q<sub>10</sub>.</div></li></ul></div><div id="riboflavin-tn.Supportive_Care"><h4>Supportive Care</h4><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>Respiratory support</div></li><li class="half_rhythm"><div>Physiotherapy to avoid contractures</div></li><li class="half_rhythm"><div>Occupational therapy for support in activities of daily living</div></li><li class="half_rhythm"><div>Orthotics for limb and trunk bracing</div></li><li class="half_rhythm"><div>Hearing aids and appropriate educational intervention for those with sensorineural hearing loss</div></li><li class="half_rhythm"><div>Speech and language therapy to avoid choking and respiratory problems</div></li><li class="half_rhythm"><div>Wheel chair as needed</div></li><li class="half_rhythm"><div>Low vision aids for those with decreased visual acuity</div></li><li class="half_rhythm"><div>Routine management of scoliosis to avoid long term respiratory problems</div></li><li class="half_rhythm"><div>Routine management of depression</div></li></ul></div></div><div id="riboflavin-tn.Surveillance"><h3>Surveillance</h3><p>Recommended follow up at three months and six months after initiation of riboflavin supplementation:</p><ul><li class="half_rhythm"><div>General examination</div></li><li class="half_rhythm"><div>Neurologic examination</div></li><li class="half_rhythm"><div>Discussion of any problems with riboflavin supplementation</div></li><li class="half_rhythm"><div>Ideally, obtaining a blood sample for riboflavin/FAD/FMN, acylcarnitine analysis (if previous evaluation demonstrated abnormalities) to determine if these levels are normalizing</div></li></ul><p>After one year of riboflavin supplementation, repeat examination/investigations as detailed in <a href="#riboflavin-tn.Evaluations_Following_Init">Evaluation Following Initial Diagnosis</a> except for consultation with a medical geneticist/genetic counselor.</p></div><div id="riboflavin-tn.AgentsCircumstances_to_Avo"><h3>Agents/Circumstances to Avoid</h3><p>Avoid dietary restriction of riboflavin. If not possible to avoid dietary restriction, provide riboflavin supplements.</p></div><div id="riboflavin-tn.Evaluation_of_Relatives_at"><h3>Evaluation of Relatives at Risk</h3><p>When the <i>SLC52A2</i> or <i>SLC52A3</i> pathogenic variants in the family are known, it is appropriate to perform <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> on the older and younger sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with riboflavin transporter deficiency neuronopathy to identify as early as possible those with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants who would benefit from early treatment with riboflavin supplementation and monitoring for potential complications of the disorder.</p><p>See <a href="#riboflavin-tn.Related_Genetic_Counseling">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="riboflavin-tn.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Females who have riboflavin transporter deficiency neuronopathy with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in either <i>SLC52A2</i> or <i>SLC52A3</i> should take riboflavin supplements before and during pregnancy and when breast feeding to avoid inducing riboflavin deficiency in the fetus and infant. Recommended doses during pregnancy are 10 mg/kg/day.</p><p>Few studies have evaluated for adverse fetal outcome after excessive maternal riboflavin intake during pregnancy. Riboflavin deficiency during pregnancy, however, has been associated with an increased risk of maternal preeclampsia and preterm delivery [<a class="bk_pop" href="#riboflavin-tn.REF.wacker.2000.38">Wacker et al 2000</a>, <a class="bk_pop" href="#riboflavin-tn.REF.carmichael.2013.579">Carmichael et al 2013</a>].</p><p>Note: Although no data are available, the authors recommend a diet rich in riboflavin during pregnancy for females who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in either <i>SLC52A2</i> or <i>SLC52A3</i> as it is unknown if they are at increased risk of developing symptoms due to an increased demand for riboflavin during pregnancy.</p></div><div id="riboflavin-tn.Therapies_Under_Investigat"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="riboflavin-tn.Genetic_Counseling"><h2 id="_riboflavin-tn_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="riboflavin-tn.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Riboflavin transporter deficiency neuronopathy is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="riboflavin-tn.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>SLC52A2</i> or one <i>SLC52A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Under normal dietary conditions carriers have no symptoms. Theoretically, carriers could have symptoms of riboflavin transporter deficiency neuronopathy if other conditions that lead to riboflavin depletion (e.g., dietary restriction, malnourishment, pregnancy, and/or illness) co-occur (see <a href="#riboflavin-tn.Pregnancy_Management">Pregnancy Management</a>).</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Under normal dietary conditions carriers have no symptoms. Theoretically, carriers could have symptoms of riboflavin transporter deficiency neuronopathy if other conditions that lead to riboflavin depletion (e.g., dietary restriction, malnourishment, pregnancy, and/or illness) co-occur (see <a href="#riboflavin-tn.Pregnancy_Management">Pregnancy Management</a>).</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with riboflavin transporter deficiency neuronopathy are obligate heterozygotes (carriers) for an <i>SLC52A2</i> or <i>SLC52A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>SLC52A2</i> or <i>SLC52A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="riboflavin-tn.Carrier_Heterozygote_Detec"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>SLC52A2</i> or <i>SLC52A3</i> pathogenic variants in the family.</p></div><div id="riboflavin-tn.Related_Genetic_Counseling"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#riboflavin-tn.Evaluation_of_Relatives_at">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="riboflavin-tn.Prenatal_Testing_and_Preim"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>SLC52A2</i> or <i>SLC52A3</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="riboflavin-tn.Resources"><h2 id="_riboflavin-tn_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Cure RTD Foundation</b></div><div><b>Phone:</b> 403-244-4549</div><div><b>Email:</b> info@cureRTD.org</div><div><a href="http://curertd.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.curertd.org</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition/brown-vialetto-van-laere-syndrome" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Brown-Vialetto-Van Laere syndrome</a></div></li><li class="half_rhythm"><div><b>Cure RTD Registry</b></div><div><a href="http://curertd.org/research/rtdregistry/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.curertd.org/research/rtdregistry</a></div></li></ul></div><div id="riboflavin-tn.Molecular_Genetics"><h2 id="_riboflavin-tn_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="riboflavin-tn.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Riboflavin Transporter Deficiency Neuronopathy: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK299312/table/riboflavin-tn.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__riboflavin-tn.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_riboflavin-tn.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_riboflavin-tn.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_riboflavin-tn.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_riboflavin-tn.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_riboflavin-tn.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_riboflavin-tn.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_riboflavin-tn.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/79581" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SLC52A2</i></a></td><td headers="hd_b_riboflavin-tn.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=79581" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">8q24<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_riboflavin-tn.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9HAB3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Solute carrier family 52, riboflavin transporter, member 2</a></td><td headers="hd_b_riboflavin-tn.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_riboflavin-tn.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SLC52A2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLC52A2</a></td><td headers="hd_b_riboflavin-tn.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SLC52A2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLC52A2</a></td></tr><tr><td headers="hd_b_riboflavin-tn.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/113278" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SLC52A3</i></a></td><td headers="hd_b_riboflavin-tn.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=113278" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">20p13</a></td><td headers="hd_b_riboflavin-tn.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9NQ40" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Solute carrier family 52, riboflavin transporter, member 3</a></td><td headers="hd_b_riboflavin-tn.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/SLC52A3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLC52A3 database</a></td><td headers="hd_b_riboflavin-tn.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SLC52A3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLC52A3</a></td><td headers="hd_b_riboflavin-tn.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SLC52A3[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLC52A3</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="riboflavin-tn.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="riboflavin-tn.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Riboflavin Transporter Deficiency Neuronopathy (<a href="/omim/211500,211530,607882,613350,614707" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK299312/table/riboflavin-tn.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__riboflavin-tn.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/211500" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">211500</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FAZIO-LONDE DISEASE</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/211530" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">211530</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BROWN-VIALETTO-VAN LAERE SYNDROME 1; BVVLS1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/607882" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">607882</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SOLUTE CARRIER FAMILY 52 (RIBOFLAVIN TRANSPORTER), MEMBER 2; SLC52A2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613350" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613350</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SOLUTE CARRIER FAMILY 52 (RIBOFLAVIN TRANSPORTER), MEMBER 3; SLC52A3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/614707" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">614707</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BROWN-VIALETTO-VAN LAERE SYNDROME 2; BVVLS2</td></tr></tbody></table></div></div><div id="riboflavin-tn.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p><i>SLC52A2</i> and <i>SLC52A3</i> encode transmembrane proteins (hRFVT2 and hRFVT3, respectively) that mediate cellular uptake of riboflavin. The water-soluble vitamin riboflavin is converted to the coenzymes flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), and is essential for normal cellular functions. These coenzymes are essential in a number of cellular processes such as normal mitochondrial function.</p><p>Although a third member of this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> family, <i>SLC52A1</i> encoding hRFVT1<i>,</i> has not been implicated directly in riboflavin transporter deficiency neuronopathy to date [<a class="bk_pop" href="#riboflavin-tn.REF.chiong.2007.109">Chiong et al 2007</a>; <a class="bk_pop" href="#riboflavin-tn.REF.ho.2011.e1976">Ho et al 2011</a>; Manole, unpublished data on 116 cases], a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>SLC52A1</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of exons 2 and 3 was identified in the mother of a child with multiple neurologic and systemic abnormalities [<a class="bk_pop" href="#riboflavin-tn.REF.ho.2011.e1976">Ho et al 2011</a>].</p><p>Early-onset weakness in the upper limbs and neck is almost invariably seen in persons with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SLC52A2</i> in contrast to those with biallelic pathogenic variants in <i>SLC52A3</i> or genetically unclassified BVVL syndrome, in whom the onset of weakness is often more generalized [<a class="bk_pop" href="#riboflavin-tn.REF.green.2010.485">Green et al 2010</a>, <a class="bk_pop" href="#riboflavin-tn.REF.bosch.2011.159">Bosch et al 2011</a>, <a class="bk_pop" href="#riboflavin-tn.REF.bosch.2012.83">Bosch et al 2012</a>, <a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al 2014</a>]. This observation could be explained by the tissue distribution of the transporters: hRFVT1 and hRFVT3 are mainly localized in the small intestinal epithelial cells and may be complimentary. In particular, hRFVT3 may transport sufficient riboflavin to prevent profound RF deficiency when there is <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a> of hRFVT1. Expression of hRFVT2 is primarily in the brain, explaining the normal circulating levels of flavins, but transport of riboflavin into the brain is impaired in hRFVT2 deficiency resulting in abnormal metabolism [<a class="bk_pop" href="#riboflavin-tn.REF.yonezawa.2013.693">Yonezawa &#x00026; Inui 2013</a>].</p><div id="riboflavin-tn.SLC52A2"><h4><i>SLC52A2</i></h4><p><b>Gene structure.</b>
<i>SLC52A2</i> produces a 1900-bp transcript, four coding exons of 445 amino acids (<a href="/nuccore/NM_024531.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_024531.4</a>). For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK299312/#riboflavin-tn.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Pathogenic variants in <i>SLC52A2</i> are distributed throughout the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in regions encoding transmembrane, intracellular, and extracellular loops [<a class="bk_pop" href="#riboflavin-tn.REF.dezfouli.2012.613">Dezfouli et al 2012</a>, <a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al 2014</a>]. Only nonsynonymous pathogenic variants in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> state have been reported in <i>SLC52A2</i> to date [<a class="bk_pop" href="#riboflavin-tn.REF.bosch.2012.83">Bosch et al 2012</a>, <a class="bk_pop" href="#riboflavin-tn.REF.spagnoli.2014.231">Spagnoli et al 2014</a>].</p><p>An <i>SLC52A2</i> founder <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been described (<a href="/nuccore/NM_024531.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_024531.4</a>:c.916G&#x0003e;A; p.Gly306Arg) in the Lebanese population [<a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al 2014</a>, <a class="bk_pop" href="#riboflavin-tn.REF.srour.2014.775">Srour et al 2014</a>].</p><p>No large insertions or deletions have been found to date [<a class="bk_pop" href="#riboflavin-tn.REF.johnson.2012.2875">Johnson et al 2012</a>, <a class="bk_pop" href="#riboflavin-tn.REF.green.2010.485">Green et al 2010</a>, <a class="bk_pop" href="#riboflavin-tn.REF.johnson.2010.567">Johnson et al 2010</a>, <a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al 2014</a>].</p><p>See <a href="/books/NBK299312/bin/riboflavin-tn-Table2.pdf">Table 2</a> (pdf) for information on pathogenic variants in <i>SLC52A2</i>.</p><p><b>In vitro analysis of specific <i>SLC52A2</i> pathogenic variants</b></p><ul><li class="half_rhythm"><div>Reduced riboflavin uptake was observed when the <i>SLC52A2</i> p.Leu123Pro and p.Leu339Pro pathogenic variants were expressed in HEK293 cells [<a class="bk_pop" href="#riboflavin-tn.REF.haack.2012.943">Haack et al 2012</a>].</div></li><li class="half_rhythm"><div>Riboflavin uptake was reduced in fibroblasts of a patient with the <i>SLC52A2</i> pathogenic variants p.[Gly419Ser];[Ser52Phe]; residual activity was 29% of controls when cells were grown in low riboflavin medium (0.4 nM) [<a class="bk_pop" href="#riboflavin-tn.REF.ciccolella.2013.104">Ciccolella et al 2013</a>]. In this patient, <i>SLC52A2</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> expression was significantly reduced (45%), while <i>SLC52A1</i> mRNA expression was unaffected; however, the protein levels of both <i>RFVT1</i> and <i>RFVT2</i> were undetectable. In vitro studies of the parents' fibroblasts suggested that the p.Ser52Phe variant may impair <i>SLC52A2</i> mRNA stability, while the p.Gly419Ser variant may affect protein function.</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al [2014]</a> determined the <sup>3</sup>H-riboflavin transport activities and protein expression in HEK293 cells transiently expressing the following <i>SLC52A2</i> variants: p.Trp31Ser, p.Gln234Stop, p.Ala284Asp, p.Tyr305Cys, p.Gly306Arg, p.Leu312Pro, and p.Leu339Pro. Cells expressing the variants displayed the greatest reduction in riboflavin uptake. The expression levels of all <i>SLC52A2</i> pathogenic variants were reduced, except p.Trp31Ser, for which expression remained near <a class="def" href="/books/n/gene/glossary/def-item/wild-type/">wild-type</a> levels in the plasma membrane [<a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al 2014</a>].</div></li></ul><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>SLC52A2</i> encodes solute carrier family 52, riboflavin transporter, member 2 (also known as riboflavin transporter 2 [hRFVT2]) comprising 445 amino acid residues.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#riboflavin-tn.Molecular_Pathogenesis">Molecular Pathogenesis</a>; see <a href="/books/NBK299312/bin/riboflavin-tn-Table2.pdf">Table 2</a> (pdf) for a summary of in vitro expression studies of <i>SLC52A2</i> pathogenic variants.</p></div><div id="riboflavin-tn.SLC52A3"><h4><i>SLC52A3</i></h4><p><b>Gene structure.</b>
<i>SLC52A3</i> produces a 2716-bp transcript, four coding exons of 469 amino acids (<a href="/nuccore/NM_033409.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_033409.3</a>). For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK299312/#riboflavin-tn.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants</b>. Pathogenic variants in <i>SLC52A3</i> are distributed throughout the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in regions encoding the transmembrane, intracellular, and extracellular loops [<a class="bk_pop" href="#riboflavin-tn.REF.dezfouli.2012.613">Dezfouli et al 2012</a>, <a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al2014</a>].</p><p>Thus far, nonsynonymous, stop-gain, frameshift, and splice-site altering pathogenic variants have been identified in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> state [<a class="bk_pop" href="#riboflavin-tn.REF.bosch.2012.83">Bosch et al 2012</a>]. No large insertions or deletions have been identified to date [<a class="bk_pop" href="#riboflavin-tn.REF.green.2010.485">Green et al 2010</a>, <a class="bk_pop" href="#riboflavin-tn.REF.johnson.2010.567">Johnson et al 2010</a>, <a class="bk_pop" href="#riboflavin-tn.REF.johnson.2012.2875">Johnson et al 2012</a>, <a class="bk_pop" href="#riboflavin-tn.REF.foley.2014.44">Foley et al 2014</a>].</p><p>See <a href="/books/NBK299312/bin/riboflavin-tn-Table2.pdf">Table 2</a> (pdf) for pathogenic variants in <i>SLC52A3</i>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>SLC52A3</i> encodes solute carrier family 52, riboflavin transporter, member 3 (also known as riboflavin transporter 3 [hRFVT3]) comprising 469 amino acid residues.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The following <i>SLC52A3</i> pathogenic variants have been shown to cause reduced riboflavin uptake: Trp17Arg, Pro28Thr, Glu36Lys, Glu71Lys, and Arg132Trp. Confocal imaging of these mutated proteins showed that they were retained within the endoplasmic reticulum as opposed to the cell surface [<a class="bk_pop" href="#riboflavin-tn.REF.nabokina.2012.652">Nabokina et al 2012</a>].</p></div><div id="riboflavin-tn.Cancer_and_Benign_Tumors"><h4>Cancer and Benign Tumors</h4><p>Genome-wide association studies (GWAS) have shown that <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> esophageal squamous cell carcinomas are associated with <a href="/SNP/snp_ref.cgi?rs=13042395" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">rs13042395</a> and <a href="/projects/SNP/snp_ref.cgi?rs=3746804" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">rs3746804</a> in <i>SLC52A3</i> [<a class="bk_pop" href="#riboflavin-tn.REF.ji.2012.982">Ji et al 2012</a>, <a class="bk_pop" href="#riboflavin-tn.REF.palmer.2012.541">Palmer et al 2012</a>, <a class="bk_pop" href="#riboflavin-tn.REF.piao.2014.798">Piao et al 2014</a>].</p></div></div></div><div id="riboflavin-tn.References"><h2 id="_riboflavin-tn_References_">References</h2><div id="riboflavin-tn.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.abarbanel.1991.349">Abarbanel JM, Ashby P, Marquez-Julio A, Chapman KR. Bulbo-pontine paralysis with deafness: the Vialetto-Van Laere syndrome. <span><span class="ref-journal">Can J Neurol Sci. </span>1991;<span class="ref-vol">18</span>:349–51.</span> [<a href="/pubmed/1913372" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1913372</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.alexander.1976.66">Alexander MP, Emery ES 3rd, Koerner FC. Progressive bulbar paresis in childhood. <span><span class="ref-journal">Arch Neurol. </span>1976;<span class="ref-vol">33</span>:66–8.</span> [<a href="/pubmed/1247398" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1247398</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.angelini.2015.615">Angelini C. Spectrum of metabolic myopathies. <span><span class="ref-journal">Biochim Biophys Acta. </span>2015;<span class="ref-vol">1852</span>:615–21.</span> [<a href="/pubmed/24997454" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24997454</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.bandettini_di_poggio.2014.141">Bandettini Di Poggio M, Monti Bragadin M, Reni L, Doria-Lamba L, Cereda C, Pardini M, Roccatagliata L, Rossi A, Schenone A. Brown-Vialetto-Van Laere syndrome: clinical and neuroradiological findings of a genetically proven patient. <span><span class="ref-journal">Amyotroph Lateral Scler Frontotemporal Degener. </span>2014;<span class="ref-vol">15</span>:141–4.</span> [<a href="/pubmed/24079556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24079556</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.bosch.2011.159">Bosch AM, Abeling NG, Ijlst L, Knoester H, van der Pol WL, Stroomer AE, Wanders RJ, Visser G, Wijburg FA, Duran M, Waterham HR. Brown-Vialetto-Van Laere and Fazio Londe syndrome is associated with a riboflavin transporter defect mimicking mild MADD: a new inborn error of metabolism with potential treatment. <span><span class="ref-journal">J Inherit Metab Dis. </span>2011;<span class="ref-vol">34</span>:159–64.</span> [<a href="/pmc/articles/PMC3026695/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3026695</span></a>] [<a href="/pubmed/21110228" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21110228</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.bosch.2012.83">Bosch AM, Stroek K, Abeling NG, Waterham HR, Ijlst L, Wanders RJ. The Brown-Vialetto-Van Laere and Fazio Londe syndrome revisited: natural history, genetics, treatment and future perspectives. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2012;<span class="ref-vol">7</span>:83.</span> [<a href="/pmc/articles/PMC3517535/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3517535</span></a>] [<a href="/pubmed/23107375" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23107375</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.brown.1894.707">Brown CH. Infantile amyotrophic lateral sclerosis of the family type. <span><span class="ref-journal">J Nerv Ment Dis. </span>1894;<span class="ref-vol">21</span>:707–16.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.carmichael.2013.579">Carmichael SL, Yang W, Shaw GM. National Birth Defects Prevention Study: maternal dietary nutrient intake and risk of preterm delivery. <span><span class="ref-journal">Am J Perinatol. </span>2013;<span class="ref-vol">30</span>:579–88.</span> [<a href="/pmc/articles/PMC4041277/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4041277</span></a>] [<a href="/pubmed/23208764" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23208764</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.chiong.2007.109">Chiong MA, Sim KG, Carpenter K, Rhead W, Ho G, Olsen RK, Christodoulou J. Transient multiple acyl-CoA dehydrogenation deficiency in a newborn female caused by maternal riboflavin deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2007;<span class="ref-vol">92</span>:109–14.</span> [<a href="/pubmed/17689999" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17689999</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.ciccolella.2013.104">Ciccolella M, Corti S, Catteruccia M, Petrini S, Tozzi G, Rizza T, Carrozzo R, Nizzardo M, Bordoni A, Ronchi D, D'Amico A, Rizzo C, Comi GP, Bertini E. Riboflavin transporter 3 involvement in infantile Brown-Vialetto-Van Laere disease: two novel mutations. <span><span class="ref-journal">J Med Genet. </span>2013;<span class="ref-vol">50</span>:104–7.</span> [<a href="/pubmed/23243084" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23243084</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.cremers.1975.330">Cremers CW, Ter Haar BG, Van Rens TJ. The Nathalie syndrome. A new hereditary syndrome. <span><span class="ref-journal">Clin Genet. </span>1975;<span class="ref-vol">8</span>:330–40.</span> [<a href="/pubmed/1204231" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1204231</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.dakhil.2010.397">Dakhil FO, Bensreiti SM, Zew MH. Pontobulbar palsy and sensorineural deafness (Brown-Vialetto-van Laere syndrome): the first case from Libya. <span><span class="ref-journal">Amyotroph Lateral Scler. </span>2010;<span class="ref-vol">11</span>:397–8.</span> [<a href="/pubmed/20001484" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20001484</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.dalla_bella.2014.1009">Dalla Bella E, Rigamonti A, Mantero V, Morbin M, Saccucci S, Gellera C, Mora G, Lauria G. Heterozygous D90A-SOD1 mutation in a patient with facial onset sensory motor neuronopathy (FOSMN) syndrome: a bridge to amyotrophic lateral sclerosis. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2014;<span class="ref-vol">85</span>:1009–11.</span> [<a href="/pubmed/24591457" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24591457</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.descatha.2006.187">Descatha A, Goddet S, Aboab J, Allary J, Gergereau A, Baer M, Fletcher D. Cardiac arrest in a patient with Brown-Vialetto-Van Laere syndrome. <span><span class="ref-journal">Amyotroph Lateral Scler. </span>2006;<span class="ref-vol">7</span>:187–8.</span> [<a href="/pubmed/16963409" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16963409</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.dezfouli.2012.613">Dezfouli MA, Yadegari S, Nafissi S, Elahi E. Four novel C20orf54 mutations identified in Brown-Vialetto-Van Laere syndrome patients. <span><span class="ref-journal">J Hum Genet. </span>2012;<span class="ref-vol">57</span>:613–7.</span> [<a href="/pubmed/22718020" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22718020</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.dipti.2005.443">Dipti S, Childs AM, Livingston JH, Aggarwal AK, Miller M, Williams C, Crow YJ. Brown-Vialetto-Van Laere syndrome; variability in age at onset and disease progression highlighting the phenotypic overlap with Fazio-Londe disease. <span><span class="ref-journal">Brain Dev. </span>2005;<span class="ref-vol">27</span>:443–6.</span> [<a href="/pubmed/16122634" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16122634</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.fazio.1892.327">Fazio M. Ereditarieta della paralisi bulbare progressiva. <span><span class="ref-journal">Riforma Med. </span>1892;<span class="ref-vol">8</span>:327.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.foley.2014.44">Foley AR, Menezes MP, Pandraud A, Gonzalez MA, Al-Odaib A, Abrams AJ, Sugano K, Yonezawa A, Manzur AY, Burns J, Hughes I, McCullagh BG, Jungbluth H, Lim MJ, Lin JP, Megarbane A, Urtizberea JA, Shah AH, Antony J, Webster R, Broomfield A, Ng J, Mathew AA, O'Byrne JJ, Forman E, Scoto M, Prasad M, O'Brien K, Olpin S, Oppenheim M, Hargreaves I, Land JM, Wang MX, Carpenter K, Horvath R, Straub V, Lek M, Gold W, Farrell MO, Brandner S, Phadke R, Matsubara K, McGarvey ML, Scherer SS, Baxter PS, King MD, Clayton P, Rahman S, Reilly MM, Ouvrier RA, Christodoulou J, Z&#x000fc;chner S, Muntoni F, Houlden H. Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. <span><span class="ref-journal">Brain. </span>2014;<span class="ref-vol">137</span>:44–56.</span> [<a href="/pmc/articles/PMC3891447/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3891447</span></a>] [<a href="/pubmed/24253200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24253200</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.gallai.1981.259">Gallai V, Hockaday JM, Hughes JT, Lane DJ, Oppenheimer DR, Rushworth G. Ponto-bulbar palsy with deafness (Brown-Vialetto-Van Laere syndrome). <span><span class="ref-journal">J Neurol Sci. </span>1981;<span class="ref-vol">50</span>:259–75.</span> [<a href="/pubmed/7229669" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7229669</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.gomez.1962.317">Gomez MR, Clermont V, Bernstein J. Progressive bulbar paralysis in childhood (Fazio-Londe's disease). Report of a case with pathologic evidence of nuclear atrophy. <span><span class="ref-journal">Arch Neurol. </span>1962;<span class="ref-vol">6</span>:317–23.</span> [<a href="/pubmed/13900073" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13900073</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.gonz_lezp_rez.2012.391">Gonz&#x000e1;lez-P&#x000e9;rez P, Lu Y, Chian RJ, Sapp PC, Tanzi RE, Bertram L, McKenna-Yasek D, Gao FB, Brown RH Jr. Association of UBQLN1 mutation with Brown-Vialetto-Van Laere syndrome but not typical ALS. <span><span class="ref-journal">Neurobiol Dis. </span>2012;<span class="ref-vol">48</span>:391–8.</span> [<a href="/pmc/articles/PMC4245016/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4245016</span></a>] [<a href="/pubmed/22766032" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22766032</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.green.2010.485">Green P, Wiseman M, Crow YJ, Houlden H, Riphagen S, Lin JP, Raymond FL, Childs AM, Sheridan E, Edwards S, Josifova DJ. Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in c20orf54. <span><span class="ref-journal">Am J Hum Genet. </span>2010;<span class="ref-vol">86</span>:485–9.</span> [<a href="/pmc/articles/PMC2833371/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2833371</span></a>] [<a href="/pubmed/20206331" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20206331</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.haack.2012.943">Haack TB, Makowski C, Yao Y, Graf E, Hempel M, Wieland T, Tauer U, Ahting U, Mayr JA, Freisinger P, Yoshimatsu H, Inui K, Strom TM, Meitinger T, Yonezawa A, Prokisch H. Impaired riboflavin transport due to missense mutations in SLC52A2 causes Brown-Vialetto-Van Laere syndrome. <span><span class="ref-journal">J Inherit Metab Dis. </span>2012;<span class="ref-vol">35</span>:943–8.</span> [<a href="/pmc/articles/PMC3470687/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3470687</span></a>] [<a href="/pubmed/22864630" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22864630</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.hardiman.2011.639">Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. <span><span class="ref-journal">Nat Rev Neurol. </span>2011;<span class="ref-vol">7</span>:639–49.</span> [<a href="/pubmed/21989247" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21989247</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.ho.2011.e1976">Ho G, Yonezawa A, Masuda S, Inui K, Sim KG, Carpenter K, Olsen RK, Mitchell JJ, Rhead WJ, Peters G, Christodoulou J. Maternal riboflavin deficiency, resulting in transient neonatal-onset glutaric aciduria Type 2, is caused by a microdeletion in the riboflavin transporter gene GPR172B. <span><span class="ref-journal">Hum Mutat. </span>2011;<span class="ref-vol">32</span>:E1976–84.</span> [<a href="/pubmed/21089064" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21089064</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.horvath.2012.679">Horvath R. Update on clinical aspects and treatment of selected vitamin-responsive disorders II (riboflavin and CoQ 10). <span><span class="ref-journal">J Inherit Metab Dis. </span>2012;<span class="ref-vol">35</span>:679–87.</span> [<a href="/pubmed/22231380" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22231380</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.houlden.2002.2681">Houlden H, Smith S, De Carvalho M, Blake J, Mathias C, Wood NW, Reilly MM. Clinical and genetic characterization of families with triple A (Allgrove) syndrome. <span><span class="ref-journal">Brain. </span>2002;<span class="ref-vol">125</span>:2681–90.</span> [<a href="/pubmed/12429595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12429595</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.houlden.2009.1366">Houlden H. The small, spastic, and furrowed tongue of Allgrove syndrome. <span><span class="ref-journal">Neurology. </span>2009;<span class="ref-vol">72</span>:1366.</span> [<a href="/pmc/articles/PMC2824517/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2824517</span></a>] [<a href="/pubmed/19365062" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19365062</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.ji.2012.982">Ji AF, Wei W, Yang JZ, Wang JS, Zhao L, Wei ZB, Lian CH, Ma L, Ma L, Wang HL, Qin XQ, Wang LD. The relationship between C20orf54 gene rs3746804 position single nucleotide polymorphism and susceptibility to esophageal squamous cell carcinoma. <span><span class="ref-journal">Zhonghua Nei Ke Za Zhi. </span>2012;<span class="ref-vol">51</span>:982–6.</span> [<a href="/pubmed/23327963" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23327963</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.johnson.2012.2875">Johnson JO, Gibbs JR, Megarbane A, Urtizberea JA, Hernandez DG, Foley AR, Arepalli S, Pandraud A, Sim&#x000f3;n-S&#x000e1;nchez J, Clayton P, Reilly MM, Muntoni F, Abramzon Y, Houlden H, Singleton AB. Exome sequencing reveals riboflavin transporter mutations as a cause of motor neuron disease. <span><span class="ref-journal">Brain. </span>2012;<span class="ref-vol">135</span>:2875–82.</span> [<a href="/pmc/articles/PMC3437022/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3437022</span></a>] [<a href="/pubmed/22740598" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22740598</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.johnson.2010.567">Johnson JO, Gibbs JR, Van Maldergem L, Houlden H, Singleton AB. Exome sequencing in Brown-Vialetto-van Laere syndrome. <span><span class="ref-journal">Am J Hum Genet. </span>2010;<span class="ref-vol">87</span>:567–9.</span> [<a href="/pmc/articles/PMC2948797/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2948797</span></a>] [<a href="/pubmed/20920669" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20920669</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.law.2009.95">Law LK, Tang NL, Hui J, Fung SL, Ruiter J, Wanders RJ, Fok TF, Lam CW. Novel mutations in ETFDH gene in Chinese patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. <span><span class="ref-journal">Clin Chim Acta. </span>2009;<span class="ref-vol">404</span>:95–9.</span> [<a href="/pubmed/19265687" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19265687</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.londe.1894.212">Londe P. Paralysie bulbaire progressive infantile et familiale. <span><span class="ref-journal">Rev Med. </span>1894;<span class="ref-vol">14</span>:212.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.malheiros.2007.32">Malheiros JA, Camargos ST, Oliveira JT, Cardoso FE. A Brazilian family with Brown-Vialetto-van Laere syndrome with autosomal recessive inheritance. <span><span class="ref-journal">Arq Neuropsiquiatr. </span>2007;<span class="ref-vol">65</span>:32–5.</span> [<a href="/pubmed/17420823" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17420823</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.manole.2014.506">Manole A, Fratta P, Houlden H. Recent advances in bulbar syndromes: genetic causes and disease mechanisms. <span><span class="ref-journal">Curr Opin Neurol. </span>2014;<span class="ref-vol">27</span>:506–14.</span> [<a href="/pubmed/25159929" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25159929</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.mcshane.1992.1889">McShane MA, Boyd S, Harding B, Brett EM, Wilson J. Progressive bulbar paralysis of childhood. A reappraisal of Fazio-Londe disease. <span><span class="ref-journal">Brain. </span>1992;<span class="ref-vol">115</span>:1889–900.</span> [<a href="/pubmed/1486466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1486466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.m_garban_.2000.117">M&#x000e9;garban&#x000e9; A, Desguerres I, Rizkallah E, Delague V, Nabbout R, Barois A, Urtizberea A. Brown-Vialetto-Van Laere syndrome in a large inbred Lebanese family: confirmation of autosomal recessive inheritance? <span><span class="ref-journal">Am J Med Genet. </span>2000;<span class="ref-vol">92</span>:117–21.</span> [<a href="/pubmed/10797435" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10797435</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.miao.2007.214">Miao J, Li H, Lin H, Su C, Liu Y, Lei G, Yang T, Li Z. Severe sleep-disordered breathing in a patient with Brown-Vialetto-Van Laere syndrome: polysomnographic findings. <span><span class="ref-journal">J Neurol Sci. </span>2007;<span class="ref-vol">263</span>:214–7.</span> [<a href="/pubmed/17669429" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17669429</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.nabokina.2012.652">Nabokina SM, Subramanian VS, Said HM. Effect of clinical mutations on functionality of the human riboflavin transporter-2 (hRFT-2). <span><span class="ref-journal">Mol Genet Metab. </span>2012;<span class="ref-vol">105</span>:652–7.</span> [<a href="/pmc/articles/PMC3309148/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3309148</span></a>] [<a href="/pubmed/22273710" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22273710</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.nalini.2013.119">Nalini A, Pandraud A, Mok K, Houlden H. Madras motor neuron disease (MMND) is distinct from the riboflavin transporter genetic defects that cause Brown-Vialetto-Van Laere syndrome. <span><span class="ref-journal">J Neurol Sci. </span>2013;<span class="ref-vol">334</span>:119–22.</span> [<a href="/pmc/articles/PMC4068726/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4068726</span></a>] [<a href="/pubmed/24139842" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24139842</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.nemoto.2005">Nemoto H, Konno S, Nomoto N, Wakata N, Kurihara T. A case of Brown-Vialetto-van Laere (BVVL) syndrome in Japan Rinsho Shinkeigaku. 2005;4:357-61. [<a href="/pubmed/15960172" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15960172</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.olsen.2007.2045">Olsen RK, Olpin SE, Andresen BS, Miedzybrodzka ZH, Pourfarzam M, Merinero B, Frerman FE, Beresford MW, Dean JC, Cornelius N, Andersen O, Oldfors A, Holme E, Gregersen N, Turnbull DM, Morris AA. ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. <span><span class="ref-journal">Brain. </span>2007;<span class="ref-vol">130</span>:2045–54.</span> [<a href="/pubmed/17584774" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17584774</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.palmer.2012.541">Palmer AJ, Lochhead P, Hold GL, Rabkin CS, Chow WH, Lissowska J, Vaughan TL, Berry S, Gammon M, Risch H, El-Omar EM. Genetic variation in C20orf54, PLCE1 and MUC1 and the risk of upper gastrointestinal cancers in Caucasian populations. <span><span class="ref-journal">Eur J Cancer Prev. </span>2012;<span class="ref-vol">21</span>:541–4.</span> [<a href="/pmc/articles/PMC3460062/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3460062</span></a>] [<a href="/pubmed/22805490" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22805490</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.piao.2014.798">Piao JM, Shin MH, Kim HN, Song HR, Kweon SS, Choi JS, Shim HJ, Hwang JE, Bae WK, Kim SH, Choi YD, Cui LH. Replication of results of genome-wide association studies on esophageal squamous cell carcinoma susceptibility loci in a Korean population. <span><span class="ref-journal">Dis Esophagus. </span>2014;<span class="ref-vol">27</span>:798–801.</span> [<a href="/pubmed/24152165" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24152165</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.rosemberg.1982.84">Rosemberg S, Lancellotti CL, Arita F, Campos C, de Castro NP Jr. Progressive bulbar paralysis of childhood (Fazio-Londe disease) with deafness. Case report with clinicopathologic correlation. <span><span class="ref-journal">Eur Neurol. </span>1982;<span class="ref-vol">21</span>:84–9.</span> [<a href="/pubmed/7094955" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7094955</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.sathasivam.2000.277">Sathasivam S, O'Sullivan S, Nicolson A, Tilley PJ, Shaw PJ. Brown-Vialetto-Van Laere syndrome: case report and literature review. <span><span class="ref-journal">Amyotroph Lateral Scler Other Motor Neuron Disord. </span>2000;<span class="ref-vol">1</span>:277–81.</span> [<a href="/pubmed/11465021" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11465021</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.sathasivam.2008.9">Sathasivam S. Brown-Vialetto-Van Laere syndrome. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2008;<span class="ref-vol">3</span>:9.</span> [<a href="/pmc/articles/PMC2346457/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2346457</span></a>] [<a href="/pubmed/18416855" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18416855</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.shankar.2000.428">Shankar SK, Gourie-Devi M, Shankar L, Yasha TC, Santosh V, Das S. Pathology of Madras type of motor neuron disease (MMND)--a histological and immunohistochemical study. <span><span class="ref-journal">Acta Neuropathol. </span>2000;<span class="ref-vol">99</span>:428–34.</span> [<a href="/pubmed/10787043" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10787043</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.spagnoli.2014.231">Spagnoli C, Pitt MC, Rahman S, de Sousa C. Brown-Vialetto-van Laere syndrome: a riboflavin responsive neuronopathy of infancy with singular features. <span><span class="ref-journal">Eur J Paediatr Neurol. </span>2014;<span class="ref-vol">18</span>:231–4.</span> [<a href="/pubmed/24206674" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24206674</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.srour.2014.775">Srour M, Putorti ML, Schwartzentruber J, Bolduc V, Shevell MI, Poulin C, O'ferrall E, Buhas D, Majewski J, Brais B, et al.  Mutations in riboflavin transporter present with severe sensory loss and deafness in childhood. <span><span class="ref-journal">Muscle Nerve. </span>2014;<span class="ref-vol">50</span>:775–9.</span> [<a href="/pubmed/24616084" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24616084</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.summers.1987.440">Summers BA, Swash M, Schwartz MS, Ingram DA. Juvenile-onset bulbospinal muscular atrophy with deafness: Vialetta-van Laere syndrome or Madras-type motor neuron disease? <span><span class="ref-journal">J Neurol. </span>1987;<span class="ref-vol">234</span>:440–2.</span> [<a href="/pubmed/3655850" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3655850</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.valmikinathan.1973.753">Valmikinathan K, Mascreen M, Meenakshisundaram E, Snehalatha C. Biochemical aspects of motor neurone disease--Madras pattern. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>1973;<span class="ref-vol">36</span>:753–6.</span> [<a href="/pmc/articles/PMC494453/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC494453</span></a>] [<a href="/pubmed/4753872" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4753872</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.van_laere.1966.289">Van Laere J. Familial progressive chronic bulbo-pontine paralysis with deafness. A case of Klippel-Trenaunay syndrome in siblings of the same family. Diagnostic and genetic problems. <span><span class="ref-journal">Rev Neurol (Paris). </span>1966;<span class="ref-vol">115</span>:289–95.</span> [<a href="/pubmed/5969547" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5969547</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.vialetto.1936.1">Vialetto E. Contributo alla forma ereditaria della paralisi bulbare progressiva. <span><span class="ref-journal">Riv. Sper. di Fren. </span>1936;<span class="ref-vol">40</span>:1.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.voudris.2002.732">Voudris KA, Skardoutsou A, Vagiakou EA. Infantile progressive bulbar palsy with deafness. <span><span class="ref-journal">Brain Dev. </span>2002;<span class="ref-vol">24</span>:732–5.</span> [<a href="/pubmed/12427524" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12427524</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.vucic.2012.73">Vucic S, Stein TD, Hedley-Whyte ET, Reddel SR, Tisch S, Kotschet K, Cros D, Kiernan MC. FOSMN syndrome: novel insight into disease pathophysiology. <span><span class="ref-journal">Neurology. </span>2012;<span class="ref-vol">79</span>:73–9.</span> [<a href="/pubmed/22722633" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22722633</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.wacker.2000.38">Wacker J, Fr&#x000fc;hauf J, Schulz M, Chiwora FM, Volz J, Becker K. Riboflavin deficiency and preeclampsia. <span><span class="ref-journal">Obstet Gynecol. </span>2000;<span class="ref-vol">96</span>:38–44.</span> [<a href="/pubmed/10862839" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10862839</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.yiu.2008.930">Yiu EM, Ravat S, Ryan MM, Shield LK, Smith LJ, Kornberg AJ. Adolescent spinal muscular atrophy with calf hypertrophy and a deletion in the SMN gene. <span><span class="ref-journal">Muscle Nerve. </span>2008;<span class="ref-vol">38</span>:930–2.</span> [<a href="/pubmed/18508340" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18508340</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="riboflavin-tn.REF.yonezawa.2013.693">Yonezawa A, Inui K. Novel riboflavin transporter family RFVT/SLC52: identification, nomenclature, functional characterization and genetic diseases of RFVT/SLC52. <span><span class="ref-journal">Mol Aspects Med. </span>2013;<span class="ref-vol">34</span>:693–701.</span> [<a href="/pubmed/23506902" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23506902</span></a>]</div></li></ul></div></div><div id="riboflavin-tn.Chapter_Notes"><h2 id="_riboflavin-tn_Chapter_Notes_">Chapter Notes</h2><div id="riboflavin-tn.Author_Notes"><h3>Author Notes</h3><p><a href="http://www.cnmd.ac.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MRC Centre for Neuromuscular Diseases</a></p><p>The authors are interested in neuromuscular diseases and channelopathies; their work involves the genetics and also the functional aspects of these disorders.</p><p>Emails for correspondence: <a href="mailto:dev@null" data-email="ku.ca.lcu@31.elonam.aeerdna" class="oemail">ku.ca.lcu@31.elonam.aeerdna</a> and <a href="mailto:dev@null" data-email="ku.ca.lcu@nedluoh.h" class="oemail">ku.ca.lcu@nedluoh.h</a></p></div><div id="riboflavin-tn.Acknowledgments"><h3>Acknowledgments</h3><p>The authors would like to thank the patients and their families for their essential help with this work. This study was supported by the Medical Research Council UK, The Wellcome Trust and The Brain Research Trust (BRT). This study was also supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC).</p></div><div id="riboflavin-tn.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>11 June 2015 (me) Review posted live</div></li><li class="half_rhythm"><div>2 September 2014 (am) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK299312</span><span class="label">PMID: <a href="/pubmed/26072523" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">26072523</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/rcdp/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/rbs/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK299312&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK299312/?report=reader">PubReader</a></li><li><a href="/books/NBK299312/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK299312" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK299312" style="display:none" title="Cite this Page"><div class="bk_tt">Manole A, Houlden H. Riboflavin Transporter Deficiency Neuronopathy. 2015 Jun 11. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK299312/pdf/Bookshelf_NBK299312.pdf">PDF version of this page</a> (489K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#riboflavin-tn.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#riboflavin-tn.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#riboflavin-tn.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#riboflavin-tn.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#riboflavin-tn.Genetically_Related_Alleli" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#riboflavin-tn.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#riboflavin-tn.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#riboflavin-tn.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#riboflavin-tn.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#riboflavin-tn.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#riboflavin-tn.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#riboflavin-tn.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=79581[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SLC52A2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=113278[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SLC52A3</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=4077796" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4077796" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4077796" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=4077796" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24253200" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2.</a><span class="source">[Brain. 2014]</span><div class="brieflinkpop offscreen_noflow">Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Foley AR, Menezes MP, Pandraud A, Gonzalez MA, Al-Odaib A, Abrams AJ, Sugano K, Yonezawa A, Manzur AY, Burns J, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Brain. 2014 Jan; 137(Pt 1):44-56. Epub 2013 Nov 19.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301503" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Disorders of Intracellular Cobalamin Metabolism</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Disorders of Intracellular Cobalamin Metabolism<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sloan JL, Carrillo N, Adams D, Venditti CP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29053833" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Clinical, pathological and functional characterization of riboflavin-responsive neuropathy.</a><span class="source">[Brain. 2017]</span><div class="brieflinkpop offscreen_noflow">Clinical, pathological and functional characterization of riboflavin-responsive neuropathy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Manole A, Jaunmuktane Z, Hargreaves I, Ludtmann MHR, Salpietro V, Bello OD, Pope S, Pandraud A, Horga A, Scalco RS, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Brain. 2017 Nov 1; 140(11):2820-2837. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301603" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glucose Transporter Type 1 Deficiency Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glucose Transporter Type 1 Deficiency Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wang D, Pascual JM, De Vivo D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=26072523" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=26072523" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040f61dde089116974a575">Riboflavin Transporter Deficiency Neuronopathy - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Riboflavin Transporter Deficiency Neuronopathy - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:39:46-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8D4509E0400B110000000005F80235&amp;ncbi_session=CE8D4509E040F611_1528SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK299312%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK299312&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK299312/&amp;ncbi_pagename=Riboflavin Transporter Deficiency Neuronopathy - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D4509E040F611_1528SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>